Holen Sie sich die Stockscreener-App
3.76
5.05%
-0.20
Handel nachbörslich:
3.82
0.06
+1.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.96
Offen:
$3.89
24-Stunden-Volumen:
3.16M
Relative Volume:
1.16
Marktkapitalisierung:
$331.85M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.2927
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-7.39%
1M Leistung:
-3.84%
6M Leistung:
-34.84%
1J Leistung:
-44.62%
1-Tages-Spanne:
$3.74
$3.98
1-Wochen-Bereich:
$3.74
$4.25
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.76 | 349.50M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune completes enrollment for Phase 2 trial in AUD study - Traders Union
Using AI based signals to follow Altimmune Inc.Sell Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Altimmune Inc. stock reach all time highs in 2025Product Launch & Comprehensive Market Scan Reports - newser.com
Automated trading signals detected on Altimmune Inc.Weekly Investment Summary & Community Consensus Stock Picks - newser.com
Can technical indicators confirm Altimmune Inc.’s reversalEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
What technical charts say about Altimmune Inc. stockTrade Analysis Report & Risk Managed Trade Strategies - newser.com
Technical analysis overview for Altimmune Inc. stockJuly 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Altimmune completes enrollment for alcohol use disorder trial By Investing.com - Investing.com Nigeria
Why Altimmune Inc. stock is a value investor pickQuarterly Trade Report & Fast Moving Stock Watchlists - newser.com
Altimmune completes enrollment for alcohol use disorder trial - Investing.com
Altimmune (ALT) Completes Enrollment for Phase 2 AUD Trial - GuruFocus
Does Altimmune Inc. show high probability of reboundJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Altimmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Clinical Trial for Pemvidutide in Alcohol Use Disorder - Quiver Quantitative
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder - The Manila Times
Should you wait for a breakout in Altimmune Inc.Stop Loss & Low Drawdown Investment Strategies - newser.com
Altimmune Inc. stock chart pattern explainedQuarterly Trade Review & Consistent Income Trade Ideas - newser.com
How strong is Altimmune Inc. stock revenue growthGlobal Markets & Weekly Momentum Stock Picks - newser.com
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
How Altimmune Inc. stock performs during Fed tightening cyclesMarket Risk Analysis & Free Low Drawdown Momentum Trade Ideas - newser.com
How to use Fibonacci retracement on Altimmune Inc.Quarterly Trade Report & High Accuracy Swing Trade Signals - newser.com
Altimmune (ALT) to Release Quarterly Earnings on Thursday - MarketBeat
Tools to monitor Altimmune Inc. recovery probability2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com
Moody Aldrich Partners LLC Invests $610,000 in Altimmune, Inc. $ALT - MarketBeat
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding - GlobeNewswire Inc.
Forecasting Altimmune Inc. price range with options dataFed Meeting & Risk Managed Investment Entry Signals - newser.com
How to forecast Altimmune Inc. trends using time seriesWatch List & Free Risk Controlled Daily Trade Plans - newser.com
What MACD and RSI say about Altimmune Inc.2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Using fundamentals and technicals on Altimmune Inc.Risk Management & Community Consensus Stock Picks - newser.com
Can momentum traders help lift Altimmune Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - newser.com
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):